Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TRVI Trevi Therapeutics

Watchlist
2.330
+0.090+4.02%
Close  12/09 16:00 ET
High
2.350
Open
2.210
Turnover
120.42K
Low
2.210
Pre Close
2.240
Volume
52.43K
Market Cap
139.62M
P/E(TTM)
Loss
52wk High
4.683
Shares
59.92M
P/E(Static)
Loss
52wk Low
0.460
Float Cap
48.75M
Bid/Ask %
-71.43%
Historical High
10.620
Shs Float
20.92M
Volume Ratio
0.81
Historical Low
0.460
Dividend TTM
--
Div Yield TTM
--
P/B
1.27
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.25%
Amplitude
6.25%
Avg Price
2.296
Lot Size
1
Float Cap
48.75M
Bid/Ask %
-71.43%
Historical High
10.620
Shs Float
20.92M
Volume Ratio
0.81
Historical Low
0.460
Dividend TTM
--
P/B
1.27
Dividend LFY
--
Turnover Ratio
0.25%
Amplitude
6.25%
Avg Price
2.296
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
CEO: Ms. Jennifer L. Good
Market: NASDAQ
Listing Date: 05/07/2019
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist